Abstract
Cardiovascular disease is more common in schizophrenia patients than in the general population, with a hypothesized contribution from increases in adiposity produced by antipsychotic medications. We sought to test the relationship between adiposity and insulin resistance using frequently sampled intravenous glucose tolerance tests (FSIVGTTs) to quantify whole-body insulin sensitivity in chronically treated patients with schizophrenia or schizoaffective disorder and untreated healthy controls. FSIVGTTs, body mass index (BMI), and waist circumference were obtained in nondiabetic patients (n=63) receiving olanzapine, risperidone, ziprasidone, or first generation antipsychotics, as well as in healthy controls (n=14). Subject groups (including untreated healthy controls) were matched for BMI and all treated patient groups were additionally matched for age. Bergman's minimal model (MinMod) was used to calculate insulin sensitivity (SI), as well as secondary measures of interest. BMI and waist circumference significantly predicted insulin sensitivity measured as MinMod SI (F(1,62)=35.11, p<0.0001 and F(1,46)=24.48, p<0.0001, respectively). In addition, BMI and waist circumference significantly predicted the acute plasma insulin response to the glucose challenge (AIRG), consistent with a β cell compensatory response to insulin resistance (MinMod AIRG F(1,65)=22.42, p<0.0001 and F(1,49)=11.72, p=0.0013, respectively). Adiposity levels occurring during antipsychotic treatment are strongly related to insulin resistance, confirming that antipsychotic-induced weight gain can contribute to increased cardiometabolic risk in this population.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ader M, Pacini G, Yang YJ, Bergman RN (1985). Importance of glucose per se to intravenous glucose tolerance. Comparison of the minimal-model prediction with direct measurements. Diabetes 34: 1092–1103.
Allebeck P (1989). Schizophrenia: a life-shortening disease. Schizophr Bull 15: 81–89.
Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al (1999). The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60: 215–220.
American Diabetes Association (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
Baroni MG, Arca M, Sentinelli F, Buzzetti R, Capici F, Lovari S et al (2001). The G972R variant of the insulin receptor substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia 44: 367–372.
Beard JC, Bergman RN, Ward WK, Porte D (1986). The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 35: 362–369.
Bergman RN (1989). Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38: 1512–1527.
Bergman RN, Phillips LS, Cobelli C (1981). Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68: 1456–1467.
Bergman RN, Prager R, Volund A, Olefsky JM (1987). Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790–800.
Bjorntorp P, Rosmond R (2000). Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 24 (Suppl 2): S80–S85.
Boehm G, Racoosin JA, Laughren TP, Katz R (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 27: 2088–2089; author reply 2089–2090.
Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al (2004). Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65: 4–18.
Davidson M (2002). Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 63 (Suppl 9): 5–11.
Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B (2001). Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 35: 196–202.
Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A (1999). The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 187: 496–502.
Elbein SC, Wegner K, Kahn SE (2000). Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds. Diabetes Care 23: 221–227.
Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB (2005). Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 162: 118–123.
Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H (1996). A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19: 1138–1141.
Harris EC, Barraclough B (1998). Excess mortality of mental disorder. Br J Psychiatry 173: 11–53.
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al (1998). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 21: 518–524.
Haupt DW (2006). Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16 (Suppl 3): S149–S155.
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62: 19–28.
Hermans MP, Levy JC, Morris RJ, Turner RC (1999a). Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42: 678–687.
Hermans MP, Levy JC, Morris RJ, Turner RC (1999b). Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 48: 1779–1786.
Herran A, de Santiago A, Sandoya M, Fernandez MJ, Diez-Manrique JF, Vazquez-Barquero JL (2000). Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 41: 373–381.
Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007). Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32: 289–297.
Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R (2002). Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr 75: 683–688.
Karter AJ, Mayer-Davis EJ, Selby JV, D’Agostino Jr RB, Haffner SM, Sholinsky P et al (1996). Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 45: 1547–1555.
Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, Willett WC, Rimm EB (2004). Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol 159: 1150–1159.
Lebovitz HE (1999). Type 2 diabetes: an overview. Clin Chem 45: 1339–1345.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290–296.
Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R (1997). Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 46: 123–129.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
Mayer-Davis EJ, Monaco JH, Hoen HM, Carmichael S, Vitolins MZ, Rewers MJ et al (1997). Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS) [see comments]. Am J Clin Nutr 65: 79–87.
McIntyre EA, Walker M (2002). Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin Endocrinol (Oxf) 57: 303–311.
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139: 802–809.
Meyer JM (2002). A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63: 425–433.
National Cholesterol Education Program (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.
National Institutes of Health (2000). The practical guide— identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication Number 00–4084.
Newcomer JW (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl 1): 1–93.
Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337–345.
Nurnberger JIJ, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849–859 discussion 863–864.
Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000). Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45: 21–28.
Overall JE (1974). A brief psychiatric rating scale in psychopharmacology research. Psychological Measurements in Psychopharmacology, Modern Problems in Pharmacopsychiatry. Karger: Basel. pp 67–78.
Peiris AN, Sothmann MS, Hoffmann RG, Hennes MI, Wilson CR, Gustafson AB et al (1989). Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 110: 867–872.
Reaven G (2003). Age and glucose intolerance: effect of fitness and fatness. Diabetes Care 26: 539–540.
Reaven GM (2005). The metabolic syndrome: requiescat in pace. Clin Chem 51: 931–938.
Resnick HE, Valsania P, Halter JB, Lin X (1998). Differential effects of BMI on diabetes risk among black and white Americans. Diabetes Care 21: 1828–1835.
Reynolds GP (2006). Metabolic syndrome and schizophrenia. Br J Psychiatry 188: 86; author reply 86–87.
Ryan MC, Collins P, Thakore JH (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160: 284–289.
Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004). Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161: 1837–1847.
Steil GM, Volund A, Kahn SE, Bergman RN (1993). Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes 42: 250–256.
Valle T, Tuomilehto J, Bergman RN, Ghosh S, Hauser ER, Eriksson J et al (1998). Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 21: 949–958.
Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamaki K et al (1999). Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 49: 159–168.
Welch S, Gebhart SS, Bergman RN, Phillips LS (1990). Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71: 1508–1518.
World Health Organization (1985). Diabetes Mellitus: Report of a WHO Study Group. World Health Organization: Geneva.
Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58–62.
Acknowledgements
Supported by MH63985 (JN), MH 67795 (DH), NARSAD (JN and DH), Pfizer Inc., Janssen Pharmaceutica, USPHS 5MO1 RR00036, and Washington University Clinical Nutrition Research Unit Center Grant nos. P30 DK56341 and P60-DK20579.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haupt, D., Fahnestock, P., Flavin, K. et al. Adiposity and Insulin Sensitivity Derived from Intravenous Glucose Tolerance Tests in Antipsychotic-Treated Patients. Neuropsychopharmacol 32, 2561–2569 (2007). https://doi.org/10.1038/sj.npp.1301392
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301392
